Former senior executive at 21st Century Oncology Inc
- GenesisCare and 21st Century Oncology post-integration – company evolution and culture shift
- Key trends and developments relating to GenesisCare’s US market presence
- Major players’ competitive positioning in the US market and different technologies, highlighting Elekta’s (STO: EKTA B) Gamma Knife and Accuray’s (NASDAQ: ARAY) CyberKnife
- GenesisCare’s US reimbursement dynamics, payer mix and main revenue drivers
- Labour challenges and outlook for H2 2022 and beyond
Gain access to Premium Content
Submit your details to access up to 5 Forum Transcripts or to request a complimentary one week trial.